Most Read Articles
Pank Jit Sin, 16 Mar 2018
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, recently received the National Pharmaceutical Regulatory Agency’s approval for an update on its indication. 

Statins have no effect on immature platelet count in CAD patients

09 Oct 2018

The use of statins does not appear to influence the immature platelet count in patients with coronary artery disease (CAD), a new study has shown.

Researchers enrolled 642 CAD patients undergoing coronary angiography, from whom blood samples were drawn upon admission and subjected to standard biochemical and blood cell count methods. Multiple logistic regression analyses were employed to determine the relationship between immature platelet count (IPC) and the use of statins.

Of the participants, 61.2 percent (n=393; mean age 68.4±9.7 years; 80.7 percent male) were on statin medication upon study admission while the remaining 38.8 percent were not (n=249; mean age 68.2±11.5 years; 73.9 percent male). Atorvastatin was the most frequently used statin (60.8 percent).

While the metabolic profile of statin-treated patients was worse (glycated haemoglobin: p=0.007; high-density lipoprotein cholesterol: p=0.005; low-density lipoprotein cholesterol: p<0.001 ), mean IPC concentration did not significantly differ between treated and nontreated participants (7.9±4.7 vs 7.7±5 x106/mL; p=0.60).

Baseline statin use likewise had no effect on the distribution of patients across IPC tertiles: tertile 1 (31 percent vs 36.1 percent), tertile 2 (34.6 percent vs 30.5 percent) and tertile 3 (34.4 percent vs 33.3 percent; p=0.36).

These findings were further validated by multivariate regression, which showed that statin use was not significantly correlated with the rate of IPC 8.4 106/mL (adjusted odds ratio, 1.19; 95 percent CI, 0.80–1.79; p=0.39).

Moreover, in 190 patients who were initiated on statin therapy upon discharge, the IPC levels at 32 days of follow-up were statistically comparable to those who were already on statin medication at study admission.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pank Jit Sin, 16 Mar 2018
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, recently received the National Pharmaceutical Regulatory Agency’s approval for an update on its indication.